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A B S T R A C T
Summary: This case report describes a 65-year-old man with a Rendu-Osler-Weber syndrome with secondary
chronic anaemia, who received multiple intravenous (IV) iron infusions and sustained diffuse bone pain sec-
ondary to multiple insufficiency fractures. Laboratory study confirmed fibroblast growth factor 23 (FGF-23)-
mediated hypophosphatemia as the main cause of a severe osteomalacia induced by ferric carboxymaltose
(FCM).
After 3 months or oral phosphate replacement and switching to iron sucrose, serum phosphate levels were
normalized and patient improved clinically.
Introduction: Some drugs can induce asymptomatic hypophosphatemia, which if sustained, can lead to a severe
osteomalacia with multiple skeletal fractures. This complication has also been described with IV iron therapy.
Methods: This case report describes a patient with Rendu-Osler-Weber syndrome with chronic iron deficiency
anaemia, recurrently treated with FCM, who developed a severe osteomalacia with multiple skeletal fractures.
Results: Laboratory study showed hypophosphatemia, with high ALP and high FGF-23. Images studies confirmed
bone mass loss and multiple insufficiency fractures. A Fluorodeoxyglucose Positron Emission Tomography/
Computed Tomography (18F-FDG PET/CT) did not show hidden tumor, so a diagnosis of FCM-induced hypo-
phosphatemic osteomalacia was performed. Phosphate replacement improved clinical symptoms of the patient.
Conclusion: Intravenous iron therapy, mainly FCM form, can cause hypophosphatemia, and in some cases induce
a severe osteomalacia with multiple fractures, so it seems advisable to monitor serum phosphate levels in high
risk patients, as those who receive repeated dose.
1. Introduction
Osteomalacia is a metabolic bone disease defined by an impairment
of bone mineralization. Skeletal fractures and bone or polyarticular
pain are the most frequent symptoms, being present in almost 90% of
cases, with predominant location in lower extremities, pelvic ring and
spine (Gifre et al., 2011). Although the main cause of osteomalacia is
vitamin D deficiency, there are other less frequent causes as impaired
vitamin D metabolism, vitamin D resistance or hypophosphatemia
(Bhan et al., 2018).
Among the causes of hypophosphatemia, are decrease in phosphate
intestinal absorption, increase in phosphate urinary excretion or phos-
phate redistribution (Gaasbeek and Meinders, 2005).
Tumor-induced osteomalacia (TIO), also known oncogenic osteo-
malacia, is a rare paraneoplastic syndrome associated with low phos-
phate and caused by small endocrine tumors that secrete the phos-
phaturic hormone, fibroblast growth factor 23 (FGF23) (Agarwal et al.,
2019; Ryan and Reiss, 1984).
Some drugs can induce a decrease in serum phosphate levels
through different mechanisms. Chronic treatment with nonabsorbable
antacids can decrease intestinal phosphate absorption (Lotz et al.,
1968). Insulin treatment of diabetic ketoacidosis, is effective to recover
metabolic acidosis, but the intracellular phosphate shift decreases
phosphate serum levels (Kebler et al., 1985). Some diuretics, tyrosine
kinase inhibitors (e.g. imatinib), or antiviral drugs (e.g. tenofovir), can
induce a renal loss of phosphate (Manghat et al., 2014).
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Ferric carboxymaltose (FCM) is an iron formulation increasingly
prescribed due to its effectiveness and fast infusion time. FCM can cause
hypophosphatemia secondary to fibroblast growth factor 23 (FGF23)
dysregulation (Glaspy et al., 2020).
In patients with chronic anaemia requiring long-term iron admin-
istration, a long-lasting hypophosphatemia can lead to osteomalacia
with associated bone pain and skeletal fractures.
Hypophosphatemia is a widely known complication of FCM treat-
ment. However, to our knowledge only few cases of FCM induced os-
teomalacia were reported (Anand and Schmid, 2017; Klein et al., 2018;
Schouten et al., 2009; Tozzi and Tozzi, 2019), being this the first case in
a patient with hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber syndrome.
2. Case report
A 65-year-old man was evaluated in the Internal Medicine out-
patient clinic because of widespread pain.
For the last 6 months prior to admission, the patient had been suf-
fering from increasing bone pain in both shoulders, pelvic girdle and
four limbs, which worsened with movements. Pain did not produce
sleep disturbance but was intensively progressing, requiring crutch and
wheelchair to move. Patient didn't refer to weakness, asthenia, fever or
constitutional symptoms such as weight loss.
Personal history of interest included sensorineural deafness, type 2
diabetes treated with insulin and sitagliptin; and HHT with iron defi-
ciency chronic anaemia due to intestinal blood loss and epistaxis.
Patient had been treated with oral ferrous sulphate for fifteen years, but
he required monthly intravenous (IV) iron treatment with FCM in the
last two years.
A previous fibrogastroscopy showed gastric and duodenal angio-
dysplasia, which was treated by ligation with elastic bands.
Three years before, the patient was diagnosed of osteoporosis, with
low bone mineral density (BMD) (T-score −2.0 at lumbar spine and
−2.2 at femoral neck) at dual-energy X-ray absorptiometry (DXA) and
a mild vertebral fracture. Serum calcium and phosphate levels were
within the normal range. He had been treated with risedronate, calcium
(500 mg/day) and vitamin D (400 IU of cholecalciferol) since then with
good adherence.
Currently retired, he worked as a jeweller. He never smoked or
drank alcohol and had a normal body mass index.
On physical examination the patient was afebrile, pale, but showed
good general condition. He had several facial and oral angiodysplasias.
He had neither swelling nor limited joints, but showed tenderness on
both shoulders, knees and femurs.
Laboratory analysis revealed calcium 9.2 mg/dL [8.8–10.2], phos-
phate 1.2 mg/L [2.7–4.5], alkaline phosphatase (ALP) 356 U/L
[40–129], 25-hydroxyvitamin D 21.8 ng/mL [optimal levels> 30],
parathyroid hormone (PTH) 82 pg/mL [10–65], creatinine 0.93 mg/dL
[0.7–1.2], 24-hour urine calcium 46.8 mg, phosphate 0.44 g, and
fractional excretion of phosphate (FEPO4) was 5.9%; serum C-terminal
FGF-23 > 419 RU/mL [reference values up to 145 RU/mL]); other
laboratory test results are shown in Table 1.
99m Tc-MDP bone scan showed multiple hot spots located in several
ribs, left scapula, bilateral sacral ala, ischiopubic and iliopubic bran-
ches, right femoral head, left tibia internal plateau and both tarsi. All
the findings were suspicious of insufficiency fractures or Looser's zones
(Fig. 1). Whole-body computed tomography and whole-body magnetic
resonance imaging excluded metastasis and confirmed multiple in-
sufficiency fractures.
A DXA scan showed a significant loss of BMD (T-score −3.14 at
lumbar spine and −3.86 at femoral neck).
With the diagnosis of FGF-23-mediated hypophosphatemic osteo-
malacia probably induced by FCM, a tumoral origin (TIO) was likewise
excluded with an 18 Fluorodeoxyglucose Positron Emission
Tomography/Computed Tomography (18F-FDG PET/CT) (Fig. 2).
Oral phosphate replacement with 3.56 g of sodium phosphate three
times a day initially, and adjusting doses in the follow-up kept serum
phosphate levels within the normal range (2.8 mg/dL and 2.7 mg dL at
the third and tenth weeks after starting the replacement, respectively
–reference values [2.7–4.5 mg/dL] with a time interval between oral
phosphate intake and blood extraction of 14 h). Patient also received
calcium and vitamin D, risedronate was discontinued and FCM was
switched to iron sucrose. During follow-up, patient's pain and mobility
gradually improved.
3. Discussion
FCM-induced hypophosphatemia is highly underdiagnosed and may
lead to a skeletal impairment with severe consequences in comorbidity
and quality of life of patients.
Although FCM-induced hypophosphatemia can be asymptomatic,
when it remains in time, as occurs in chronic conditions may result in
severe osteomalacia, as in our patient.
Our patient was previously diagnosed of osteoporosis with a mild
vertebral fracture, but with his BMD in the range of osteopenia. He had
a normal serum calcium and phosphate and was treated with oral bi-
sphosphonates, calcium and vitamin D for the last 3 years.
Although he didn't suffer any new vertebral or non-vertebral frac-
ture, a progressive impairment of bone mineralization was the cause of
a widespread bone pain as first symptom of osteomalacia. Bone scan
showed multiple insufficiency fractures.
Osteomalacia has been reported with non-nitrogen containing bi-
sphosphonates but not with third generation bisphosphonates, like ri-
sedronate.
The presence of hypophosphatemia, 24-hour urine phosphate>
100 mg and FEPO4 > 5% and high FGF-23, indicated renal phosphate
wasting, hence considering the history of recurrent previous infusions
of FCM made us suspect this complication.
Several diseases can cause chronic blood loss requiring IV iron
therapy, mainly erosive gastritis, peptic ulcer, diverticulitis, benign
tumors, inflammatory bowel disease, angiodysplasia, haemorrhoids and
chronic haemolysis (Camaschella, 2015).
Our patient had a HHT, an autosomal dominant inherited disease in
which patients commonly had anaemia due to chronic digestive losses
as hematemesis or melena in 33% (Kjeldsen and Kjeldsen, 2000). As far
as we are concerned, this is the first case in the literature of FCM-
Table 1
Baseline laboratory data.
Variable Patient Reference range
Hemoglobin, g/L 8.4 130–175
Calcium, mg/dL 9.2 8.8–10.2
Phosphate, mg/L 1.2 2.7–4.5
Gamma-glutamyl transferase, U/L 10 8–61
Alkaline phosphatase, U/L 356 40–129
25-Hydroxyvitamin D, ng/mL 21.8 > 30
Parathyroid hormone, pg/mL 82 10–65
Creatinine, mg/dL 0.93 0.7–1.2
Glomerular filtration rate CKD-EPI mL/min/1.73 m2 87.5 > 60
Thyrotropin, μU/mL 2.15 0.4–4.0
Cortisol, μg/dL 17.9 6.02–18.4
Total testosterone, ng/mL 7.18 1.93–7.40
Tryptase, μg/L 5.3 0–11
24-Hour urine calcium, mg/d 46.8 100–300
24-Hour urine phosphate, g/d 0.44 0.4–1.3
Fractional excretion of phosphate, % 5.9 < 5
Serum C-terminal FGF-23, RU/mL >419 <145
Prostate specific antigen, ng/mL 0.9 0–4
IgG lambda, g/L 1.21
IgM lambda, g/L 1.48
FGF-23: fibroblast growth factor 23; CKD-EPI: Chronic Kidney Disease
Epidemiology Collaboration.
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induced hypophosphatemic osteomalacia in a patient with HHT.
Severe hypophosphatemia is an IV iron treatment side effect firstly
described by Okada M et al. in 1983 (Okada et al., 1983). Despite the
heterogeneous methodology of the studies and the different definition
of hypophosphatemia, FCM is the form of IV iron most frequently
associated with this complication. In a recent systematic literature re-
view hypophosphatemia associated to IV iron therapies was reported in
19 randomized control trials (Glaspy et al., 2020). This complication
has been observed in 0.0–92.1% patients treated with FCM (18 studies),
0.0–40.0% treated with iron sucrose (5 studies), 0.4% treated with
Fig. 1. Bone scintigraphy with revealed a characteristic metabolic pattern with a generalized increased uptake in axial skeleton. Multiple hypercaptive foci consistent
with insufficiency fractures or Looser's zones were observed in multiple bilateral rib, left scapula, bilateral sacral ala, ischiopubic and iliopubic branches, right
femoral head, left tibia internal plateau and both tarsi.
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ferumoxytol (1 study), and 0.0% treated with low-molecular-weight
iron dextran (1 study).
FCM is a IV effective and safe iron formulation taken up by the
reticuloendothelial cells and released gradually to the serum, with little
risk of release of cytotoxic free iron into the circulating blood (Ikuta
et al., 2019).
Despite the mechanism by which FCM raises FGF-23 remains un-
known it has been proposed that certain carbohydrate moieties present
in FCM can inhibit the degradation of FGF-23 (Wolf et al., 2013), re-
sulting in proximal tubular reabsorption of phosphate reduction and
active form of vitamin D decrease (Holick, 2007; Wolf et al., 2020).
Secondary hyperparathyroidism, as we saw in our patient, due to hy-
pocalcemia caused by decreased 1,25-dihydroxyvitamin D also can
make a part in increased phosphate clearance. However, high PTH
actually leads to normal calcium levels and hypophosphatemia. In ad-
dition animal models have shown that FGF-23 reduces 1,25-dihydrox-
yvitamin D by reducing its production and increasing its degradation
(Shimada et al., 2004).
FCM-induced hypophosphatemia has been reported to be transient
and asymptomatic in most cases, so serum phosphate levels of patients
treated with FCM do not need to be checked or monitored in most cases
(Ikuta et al., 2019). Nevertheless, in patients with existing risk factors,
such as severe malnutrition, vitamin D deficiency or after prolonged
exposure to high dose IV iron, as in the case of our patient, hypopho-
sphatemia may require medical attention.
Another cause of hypophosphatemic osteomalacia is TIO, which can
be identical to FCM-induced osteomalacia, in which indolent me-
senchymal tumors, with slow growth are responsible of an over-
production of FGF-23 leading to an increase urinary phosphate excre-
tion (Ryan and Reiss, 1984). Although not completely ruled it out, a
whole-body 18F-FDG PET/CT did not show a hidden tumor.
Vitamin D plays an important role in bone mineralization, and low
vitamin D levels can contribute to osteomalacia. Although our patient
was receiving vitamin D supplementation (400 IU/day of cholecalci-
ferol) he had vitamin D insufficiency (21 ng/mL) at presentation.
Maybe the dose of cholecalciferol was insufficient to keep higher 25-
hydroxyvitamin D levels.
25-Hydroxyvitamin D and phosphate serum levels were normalized
after vitamin D and sodium phosphate replacement in addition to
switching to another iron therapy. Serum phosphate levels often fluc-
tuate in patients with oral phosphate supplementation and it depends
on the time since the last dose. However, in our patient serum phos-
phate levels were within the normal range in several blood tests with a
regular time interval between oral intake and blood extraction. Patient
also received calcium and vitamin D, risedronate was discontinued and
FCM was switched to iron sucrose. During follow-up, patient's pain and
mobility gradually improved.
This case highlights that although a single or few infusions of IV iron
therapy is usually safe, in cases requiring multiple doses it could be
advisable to monitor closely phosphate serum levels and normalize 25-
hydroxyvitamin D deficiency.
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